Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Seems so undervalued but am cautious about adding more at the moment as this is already the largest holding in my portfolio
Well it’s impossible to release a new drug with out going through the right sequences and Dose level is one of those
Dose levels, I would have thought that they would have been doing dose levels when they have been giving it to patients or have they just been guessing lol
Trials 252 patients study 240...maybe they have a 5% leeway incase patients drop out, just a thought
I think not as this trial is to evaluate dose level
The others are for effectiveness in COVID-19 patients
GLA invested.
so..is this study anyway related to these ..which was posted by Philmccrotch ??
https://clinicaltrials.gov/ct2/show/NCT05037162?term=Cimetra&draw=2&rank=2
so....is there a "trial" of 252 patients and a "study" of 240 patients.... a bit confusing to be honest
can anyone clarify ??
Nice buys coming in GLA
getting any FDA approvals/licence does generally take time ...needs plenty of patience ...and they are quite specific about how any trial is carried out and what results are required ..and all that ....a case of just keeping going and completing each step they request , in the exact way they require it
kpleat
gotta you... the 252 patients ..." recruiting" ...so..ongoing one assumes
Philmccrotch
240 patients .
Estimated Study Start Date : September 2021
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : February 2022 -
although there is states " Multi-center multinational-controlled study in Israel, Brazil, Spain, and South-Africa." and mentions "Phase 2" ... trial using two different doses and a placebo
It does however give a lot of detail as to what goes into such trials and how many steps have to be taken and measured and required doctor visits etc ...it is really quite an involved and detailed process
Feb 2022 - was what was pencilled in previously with the added 3 month further FDA required study ..if I remember
In the FDA search there are now two trials for Cimetra with one being created on setpember 8th.
https://clinicaltrials.gov/ct2/show/NCT05037162?term=Cimetra&draw=2&rank=2
Thoughts?